Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
BIIB · Nasdaq · United States · Biological Products, (No Diagnostic Substances)
In shortBIOGEN INC. is profitable, generates cash and carries moderate debt, with revenue growing (+2.2% last year).
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | – | n/a |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 13.1% | 72/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 7.4% | 37/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.68× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.34× | 92/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | – | n/a |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 20.7% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.59× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 4 of 5 | 0/100 |
| Revenue growth volatility | 7.9% | 82/100 |
| Operating margin volatility | – | n/a |
Weight in the score: 20%
| Revenue growth, 3-year average | -0.9% | 11/100 |
|---|---|---|
| EPS growth, 3-year average | -25.0% | 0/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 10,982 | 10,173 | 9,836 | 9,676 | 9,891 |
| Cost of revenue | 2,110 | 2,278 | 2,533 | 2,310 | 2,404 |
| Gross profit | 8,872 | 7,895 | 7,302 | 7,366 | 7,486 |
| Research & development | 2,501 | 2,231 | 2,445 | 1,980 | 1,779 |
| Selling, general & admin | 2,674 | 2,404 | 2,550 | 2,404 | 2,434 |
| Operating income | 2,841 | – | – | – | – |
| Interest expense | 254 | 247 | 247 | 250 | 268 |
| Pre-tax income | 1,745 | 3,592 | 1,297 | 1,906 | 1,557 |
| Income tax | 53 | 633 | 135 | 274 | 264 |
| Net income | 1,556 | 3,047 | 1,161 | 1,632 | 1,293 |
| Diluted EPS | $10.40 | $20.87 | $7.97 | $11.18 | $8.79 |
| Diluted shares (millions) | 150 | 146 | 146 | 146 | 147 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of BIOGEN INC. are included in the Investor plan. Try free for 7 days →
Not computed: a required balance-sheet item is missing.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Apr 29, 2026